|
|
LSBC MEMBER NEWS ANNOUNCEMENTS
|
As a member benefit, LifeSciences BC publishes all our member news releases as we receive them. If you are a member and would like to have your news release published in
BioLinks, send them along to Susan Ogilvie at
sogilvie@lifesciencesbc.ca . Please include you company logo and a point of contact in the release.
Our BioLInks data shows us that we have an open rate of 39% with our member news getting the highest click - open rate. With a subscriber circulation of 4000+ readers, the data tells us the member news is a valuable read for our subscribers! So please, keep us up to date with your news - we all enjoy hearing about it!
|
|
President and CEO, LifeSciences BC
Wendy Hurlburt
|
|
The week has "zoomed" by and we have been busy attending virtual conferences that are connecting us to exciting global audiences and opportunities. Last week we attended Life Science Innovation Northwest presented by Life Science Washington, a two-day virtual event which brought together the life science community to discuss and feature some of the most compelling technology breakthroughs in the region.
We attended many great sessions and met with companies such as
Imec
, a world-leading R&D and innovation hub in nanoelectronics and digital technologies and Emergent BioSolutions, a multinational specialty biopharmaceutical company that focuses on emerging public health threats. During the networking component, we were able to
profile the innovative BC Life Sciences sector and LSBC members.
The companies we met with had reached out specifically to make connections in British Columbia and discover ways in which they could partner with our members. It was wonderful to connect with international companies who expressed an interest in our life science sector. We are clearly on the international radar, as we have experienced many follow-up meetings with foreign governments, academic institutions and companies, from events like BIO. COVID has not slowed down our outreach and connectivity, some say it has emboldened it.
Next week’s BioLinks will be the last one for this summer but we will continue to post news announcements on our website and broadcast on social media, so please continue to share your news with us. We will return to our regular BioLinks schedule on Thursday, September 3
rd
.
|
|
|
|
DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals
|
Conference Call to be held Thursday, July 23, 2020 at 4:30pm ET
SAN DIEGO, July 17, 2020 /PRNewswire/ —
DelMar Pharmaceuticals, Inc.
(Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today that it will be conducting a conference call to discuss the Company’s previously announced proposed acquisition of Adgero BioPharmaceuticals Holdings, Inc.
READ MORE
|
|
|
|
Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis
|
VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted
...
READ MORE
|
|
|
|
ASPECT BIOSYSTEMS APPOINTS ERIC ROOS AS CHIEF BUSINESS DEVELOPMENT OFFICER
|
VANCOUVER, British Columbia – July 21, 2020 – Aspect Biosystems, a biotechnology platform company pioneering the microfluidic 3D bioprinting of human tissues, is pleased to announce the appointment of Eric Roos as its new Chief Business Development Officer.
READ MORE
|
|
|
|
Aurinia Announces Public Offering of Common Shares
|
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has commenced a registered underwritten public offering of its common shares (the “Offering”).
READ MORE
|
|
|
|
Aurinia Prices US$200 Million Public Offering of Common Shares
|
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 13,333,334 common shares (the “Offering”).
READ MORE
|
|
|
|
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates
|
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that the American Association of Pharmaceutical Scientists ("AAPS") has accepted two presentations regarding iCo's Oral Amphotericin B technology (iCo-019) for the AAPS 2020 PharmSci 360 Meeting to be held October 26-November 5, 2020 (the "PharmSci 360 Meeting").
READ MORE
|
|
 |
Norton Rose Fulbright is a global law firm. Their life sciences and healthcare teams in Canada, the US and around the world have a strong reputation for working with an array of innovative pharmaceutical, medical device and biotechnology companies at all stages in the company and product life cycles.
|
|
|
|
Established in Vancouver, Canada in 2016, Onestep Laboratories Inc. draws upon years of experience in biochemistry and diagnostics to develop leading-edge reagents for biological laboratories. Their goal is to provide fellow scientists with high quality, cost effective products.
|
|
|
|
Community - Sector Interest
|
|
|
|
Seeking input for BC COVID-19 Strategic Research Framework
|
1) Enabling Rapid Research Response
There are a variety of structures in place to facilitate research including expedited ethics processes and rapid data access.
2) Research Priorities
Work is under way to better understand the impact of COVID-19 and its control measures.
3) Knowledge Translation
What additional processes/approaches should be introduced to facilitate the production and use of research findings by decision-makers? By the public?
4) Additional Feedback
Are there any other considerations you would like to see included in the strategic research framework?
|
|
|
|
Biotech venture capital firm taps Ontario, B.C. funds, recruits investing pioneer as Canadian sector heats up
|
One of Canada’s most successful biotechnology venture capital groups has drawn rare domestic institutional backing from outside Quebec and recruited one of the country’s pioneering investors in the space, further signs of the thriving sector’s resurgence.
READ MORE
|
|
|
|
B.C. appoints new innovation commissioner
|
Gerri Sinclair has been appointed as B.C.’s new innovation commissioner, effective July 17, 2020. Sinclair will serve as advocate for the province’s tech sector.
READ MORE
|
|
|
|
OBIO Announces First Eight Early Adopter Health Network Projects to Drive Innovation into the Health System
|
|
|
|
BDC to give $160 million to IP-rich companies which struggle to access capital
|
MONTREAL -- The Business Development Bank of Canada is pledging $160 million for companies that are rich in intellectual property, but often struggle to access capital.
READ MORE
|
|
|
|
Update: Student Work Placement Program now open to healthcare placements
|
The Student Work Placement Program is now accepting applications for healthcare placements. Canada’s healthcare industry has a growing need to produce job-ready healthcare workers. There are 1,500 open spots available in 2020-21.
WEBSITE
|
|
|
|
Posting A JOB on the LSBC Website
|
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's
The Petri Dish
After your first five reposts, you will also receive 25% off all job postings on
The Petri Dish
. Want more info?
CONTACT: Sue Callaghan -
talent@lifesciencesbc.ca
|
|
|
|
Membership Benefits Program
COST SAVINGS FOR OUR MEMBERS
As a LifeSciences BC member, organizations and their employees can benefit from significant savings on a range of business and personal services, thanks to our Membership Benefits Program partnerships. You can locate the cost savings program suited to you needs
here
.
|
|
|
|
|
|
|
